Everolimus + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis

Conditions

Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma

Trial Timeline

Aug 1, 2009 → Oct 1, 2014

NCT ID

NCT00789828

About Everolimus + Placebo

Everolimus + Placebo is a phase 3 stage product being developed by Novartis for Tuberous Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00789828. Target conditions include Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma.

What happened to similar drugs?

1 of 7 similar drugs in Tuberous Sclerosis were approved

Approved (1) Terminated (1) Active (5)

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

🔄Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3

🔄RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3

🔄everolimusNovartisPhase 3

❌GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01529554	Phase 1/2	Completed	Jan 8, 2015	Nov 29, 2021	Acute Coronary Syndromes
NCT01524783	Phase 3	Completed	Mar 30, 2012	Aug 7, 2020	Advanced NET of GI Origin
NCT01133678	Phase 2	Terminated	May 4, 2010	Jan 1, 2015	Head and Neck Cancer
NCT00789828	Phase 3	Completed	Aug 1, 2009	Oct 1, 2014	Tuberous Sclerosis

Competing Products

13 competing products in Tuberous Sclerosis

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
RAD001	Novartis	Phase 1/2	32
Placebo + Everolimus (RAD001)	Novartis	Phase 2	31
RAD001 + Placebo	Novartis	Phase 2	35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
Everolimus	Novartis	Phase 1/2	32
everolimus (RAD001)	Novartis	Phase 1/2	32
everolimus	Novartis	Phase 3	44
sirolimus	Pfizer	Phase 2	31
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29
GWP42003-P	Jazz Pharmaceuticals	Phase 3	37
GWP42003-P + Placebo	Jazz Pharmaceuticals	Phase 3	37
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	44